RegeneRx Biopharmaceuticals, Inc.

RGRX

US75886X3061

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 10:45:27 01/05/2024 pm IST			5-day change	1st Jan Change
0.0014 ^USD	0.00%		0.00%	+16.67%

2023	RegeneRx Biopharmaceuticals, Inc. announced that it has received $0.05 million in funding from Essetifin S.p.A.	CI
2023	RegeneRx Biopharmaceuticals, Inc. announced that it expects to receive $0.175 million in funding	CI

Regenerx Biopharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020

August 15, 2020 at 01:42 am IST

RegeneRx Biopharmaceuticals, Inc. announced earnings results for the second quarter ended June 30, 2020. For the second quarter, the company announced sales was USD 19,191 compared to USD 19,190 a year ago. Operating loss was USD 385,235 compared to USD 351,946 a year ago. Net loss was USD 436,161 compared to USD 388,448 a year ago. For the half year, sales was USD 38,381 compared to USD 38,381 a year ago. Operating loss was USD 723,383 compared to USD 674,807 a year ago. Net loss was USD 822,894 compared to USD 720,899 a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.01 a year ago.

Latest news about RegeneRx Biopharmaceuticals, Inc.

RegeneRx Biopharmaceuticals, Inc. announced that it has received $0.05 million in funding from Essetifin S.p.A.	03/23/03	CI
RegeneRx Biopharmaceuticals, Inc. announced that it expects to receive $0.175 million in funding	13/23/13	CI
RegeneRx Biopharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	16/23/16	CI
RegeneRx Biopharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	12/23/12	CI
RegeneRx Biopharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	11/23/11	CI
Thymosin Beta 4 Research Leads Toward Potential Future Anti-Aging Therapy	31/23/31	CI
Regenerx Biopharmaceuticals, Inc. Reports New Scientific Publication of RGN-259 Phase 3 Clinical Trial Results in Patients with Neurotrophic Keratopathy	03/23/03	CI
RegeneRx Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	15/22/15	CI
Regenerx Licensee Submits Special Protocol Assessment to Fda for 4Th Phase 3 Clinical Trial for Dry Eye Disease	24/22/24	CI
RegeneRx Biopharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	13/22/13	CI
RegeneRx Biopharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	17/22/17	CI
RegeneRx Biopharmaceuticals, Inc. Reports that Researchers Demonstrate the Therapeutic Efficacy of Thymosin Beta 4	04/22/04	CI
RegeneRx Biopharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	31/22/31	CI
RegeneRx Biopharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	30/22/30	CI
Researchers Confirm Thymosin Beta 4's Ability to Protect Eyes From Ethanol Injury	25/22/25	CI
RegeneRx Biopharmaceuticals, Inc. Announces U.S. FDA Accepts Request for Pre-BLA meeting Pursuant to RGN-259	17/21/17	CI
RegeneRx Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	16/21/16	CI
RegeneRx Biopharmaceuticals, Inc. Announces Clinical Results of RGN-259 for the Treatment of Neurotrophic Keratitis to be Presented at 2021 American Ophthalmology Association Meeting	29/21/29	CI
RegeneRx Biopharmaceuticals, Inc. Announces New Research Demonstrates Thymosin Beta 4's Potential Positive Effects on Alzheimer's Disease	05/21/05	CI
Regenerx Biopharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	07/21/07	CI
RegeneRx JV Updates RGN-259 Regulatory Progress for Dry Eye Syndrome	14/21/14	CI
RegeneRx Biopharmaceuticals, Inc. announced that it has received $1.98 million in funding	30/21/30	CI
RegeneRx Biopharmaceuticals, Inc. announced that it expects to receive $2 million in funding	28/21/28	CI
Regenerx Biopharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	15/21/15	CI
RegeneRx Biopharmaceuticals, Inc. Reports Topline Results of ARISE-3 Dry Eye Trial	18/21/18	CI

Chart RegeneRx Biopharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

RegeneRx Biopharmaceuticals, Inc. (RegeneRx) is a biopharmaceutical company. The RegeneRx is focused on the development of a therapeutic peptide Thymosin beta 4(Tb4) for tissue and organ protection, repair, and regeneration. RegeneRx operates in the development and marketing of Tb4, an amino acid peptide. Tb4 is a synthetic copy of a naturally occurring 43-amino acid peptid originally isolated from bovine thymus glands. The Company's product candidates in clinical development includes RGN-259, RGN-352, and RGN-137. The Company's RGN -259 is a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease or other pathology. RGN-352 is an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases. Its RGN-137 is a topical gel for dermal wounds and reduction of scar tissue.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Biopharmaceuticals

	1st Jan change	Capi.
REGENERX BIOPHARMACEUTICALS, INC.	+16.67%	2.11T
CSL LIMITED	-2.32%	9.04TCr
SAMSUNG BIOLOGICS CO.,LTD.	+3.68%	4.14TCr
BIOGEN INC.	-10.90%	3.36TCr
UCB	+58.05%	2.57TCr
BIOMARIN PHARMACEUTICAL INC.	-19.56%	1.47TCr
INCYTE CORPORATION	-9.06%	1.28TCr
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.34%	1.17TCr
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.53%	1.14TCr
SWEDISH ORPHAN BIOVITRUM AB	+3.75%	879.22Cr

Biopharmaceuticals